Lymphoma & CLL Subtypes

SYMPATICO study safety run-in: simultaneous ibrutinib plus venetoclax for R/R MCL

Mantle cell lymphoma (MCL) is an aggressive B-cell non-Hodgkin lymphoma lacking therapeutic options that prolong...

FDA accepts new drug application for parsaclisib for R/R FL, MZL, and MCL

Non-Hodgkin lymphomas (NHLs) are a varied group of lymphatic cancers that may be indolent or aggressive, and while some...

Educational Theme | AITL: Pathophysiology, diagnostic challenges, and current and future treatment of a rare T-cell lymphoma subtype

Angioimmunoblastic T-cell lymphoma (AITL) is a subtype of mature...

What does the future of T-cell lymphoma management look like?

During Lymphoma Leukemia & Myeloma 2021 Virtual Congress, the Lymphoma Hub was pleased to speak to Jia Ruan, Weill Cornell Medicine, New...

What role is there for allogeneic SCT in the treatment of Hodgkin lymphoma?

During The 6th International Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM 2021),...

Efficacy and safety of pembro-GVD as second-line therapy for patients with R/R cHL

Most patients with classical Hodgkin lymphoma (cHL) are cured with frontline therapy, but some patients with advanced...

How can we address treatment disparities in patients with T-cell lymphoma?

During the Society of Hematologic Oncology (SOHO) 2021 Annual Meeting, the Lymphoma Hub was pleased to speak to Mary Jo...

CPI-613® (Devimistat) receives orphan drug designation for the treatment of patients with relapsed or refractory Burkitt lymphoma by the European Medicines Agency

Burkitt lymphoma (BL) is an extremely...